JP7783628B2 - 多層rnaナノ粒子 - Google Patents

多層rnaナノ粒子

Info

Publication number
JP7783628B2
JP7783628B2 JP2022503898A JP2022503898A JP7783628B2 JP 7783628 B2 JP7783628 B2 JP 7783628B2 JP 2022503898 A JP2022503898 A JP 2022503898A JP 2022503898 A JP2022503898 A JP 2022503898A JP 7783628 B2 JP7783628 B2 JP 7783628B2
Authority
JP
Japan
Prior art keywords
rna
tumor
pharmaceutical composition
nanoparticle
nanoparticles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022503898A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022541586A (ja
Inventor
セイヤー、エリアス
メンデス-ゴメス、ヘクター、ルーベン
ミッチェル、デュエイン
リナルディ、カルロス
Original Assignee
ユニバーシティ オブ フロリダ リサーチ ファンデーション インコーポレーティッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユニバーシティ オブ フロリダ リサーチ ファンデーション インコーポレーティッド filed Critical ユニバーシティ オブ フロリダ リサーチ ファンデーション インコーポレーティッド
Publication of JP2022541586A publication Critical patent/JP2022541586A/ja
Priority to JP2025089202A priority Critical patent/JP2025138644A/ja
Application granted granted Critical
Publication of JP7783628B2 publication Critical patent/JP7783628B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0033—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being non-polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Dispersion Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2022503898A 2019-07-19 2020-07-17 多層rnaナノ粒子 Active JP7783628B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025089202A JP2025138644A (ja) 2019-07-19 2025-05-28 多層rnaナノ粒子

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201962876440P 2019-07-19 2019-07-19
US62/876,440 2019-07-19
US201962877598P 2019-07-23 2019-07-23
US62/877,598 2019-07-23
US201962884983P 2019-08-09 2019-08-09
US62/884,983 2019-08-09
US201962933326P 2019-11-08 2019-11-08
US62/933,326 2019-11-08
PCT/US2020/042606 WO2021016106A1 (en) 2019-07-19 2020-07-17 Multilamellar rna nanoparticles

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025089202A Division JP2025138644A (ja) 2019-07-19 2025-05-28 多層rnaナノ粒子

Publications (2)

Publication Number Publication Date
JP2022541586A JP2022541586A (ja) 2022-09-26
JP7783628B2 true JP7783628B2 (ja) 2025-12-10

Family

ID=74193752

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022503898A Active JP7783628B2 (ja) 2019-07-19 2020-07-17 多層rnaナノ粒子
JP2025089202A Pending JP2025138644A (ja) 2019-07-19 2025-05-28 多層rnaナノ粒子

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025089202A Pending JP2025138644A (ja) 2019-07-19 2025-05-28 多層rnaナノ粒子

Country Status (8)

Country Link
US (1) US20220287969A1 (cg-RX-API-DMAC7.html)
EP (1) EP3999034A4 (cg-RX-API-DMAC7.html)
JP (2) JP7783628B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220035434A (cg-RX-API-DMAC7.html)
AU (2) AU2020316335B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022000925A2 (cg-RX-API-DMAC7.html)
CA (1) CA3144388A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021016106A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3168509A1 (en) * 2020-02-19 2021-08-26 Elias SAYOUR Multilamellar rna nanoparticles and methods of sensitizing tumors to treatment with immune checkpoint inhibitors
AU2021247163A1 (en) * 2020-04-01 2022-10-20 University Of Florida Research Foundation, Incorporated Multilamellar RNA nanoparticle vaccine against SARS-CoV-2
US20240238418A1 (en) * 2021-05-07 2024-07-18 University Of Florida Research Foundation, Inc. Car t cell therapy method
WO2024263713A1 (en) * 2023-06-21 2024-12-26 University Of Florida Research Foundation, Incorporated Materials and methods of using proinsulin mrna nanoparticles

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016537304A (ja) 2013-09-26 2016-12-01 バイオンテック アーゲー Rnaによるシェルを含む粒子
JP2017520549A (ja) 2014-06-26 2017-07-27 ラモット アット テル アビブ ユニバーシティ, リミテッド 核酸の送達のためのリポソーム製剤

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011112597A1 (en) * 2010-03-08 2011-09-15 Northeastern University Magnetic nanoplatforms for theranostic and multi-modal imaging applications
KR20220025112A (ko) * 2011-06-08 2022-03-03 샤이어 휴먼 지네틱 테라피즈 인크. Mrna 전달을 위한 지질 나노입자 조성물 및 방법
EA201492055A1 (ru) * 2012-06-08 2015-11-30 Шир Хьюман Дженетик Терапис, Инк. ИНГАЛЯЦИОННАЯ ДОСТАВКА мРНК В НЕЛЕГОЧНЫЕ КЛЕТКИ-МИШЕНИ
ITRM20120480A1 (it) * 2012-10-09 2014-04-10 Uni Degli Studi Camerino Nanoparticelle lipidiche multicomponenti e procedimenti per la loro preparazione.
WO2017062502A1 (en) * 2015-10-05 2017-04-13 The Regents Of The University Of Colorgo, A Body Corporate Lipoplexes formulated for catalytic delivery
US20210077399A1 (en) * 2018-05-08 2021-03-18 University Of Florida Research Foundation, Incorporated Magnetic liposomes and related treatment and imaging methods
WO2020037102A1 (en) * 2018-08-15 2020-02-20 University Of Florida Research Foundation, Inc. Methods of sensitizing tumors to treatment with immune checkpoint inhibitors
US20220054610A1 (en) * 2018-09-12 2022-02-24 University Of Florida Research Foundation, Inc. Slow-cycling cell-rna based nanoparticle vaccine to treat cancer
US20230096704A1 (en) * 2020-02-05 2023-03-30 University Of Florida Research Foundation, Incorporated Rna-loaded nanoparticles and use thereof for the treatment of cancer
CA3168509A1 (en) * 2020-02-19 2021-08-26 Elias SAYOUR Multilamellar rna nanoparticles and methods of sensitizing tumors to treatment with immune checkpoint inhibitors
AU2021247163A1 (en) * 2020-04-01 2022-10-20 University Of Florida Research Foundation, Incorporated Multilamellar RNA nanoparticle vaccine against SARS-CoV-2
US20240299516A1 (en) * 2020-12-21 2024-09-12 University Of Florida Research Foundaton, Inc. Multilamellar rna nanoparticle vaccine against cancer
US20240238418A1 (en) * 2021-05-07 2024-07-18 University Of Florida Research Foundation, Inc. Car t cell therapy method
US20250231177A1 (en) * 2022-04-04 2025-07-17 University Of Florida Research Foundation, Inc. Method of characterizing tumors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016537304A (ja) 2013-09-26 2016-12-01 バイオンテック アーゲー Rnaによるシェルを含む粒子
JP2017520549A (ja) 2014-06-26 2017-07-27 ラモット アット テル アビブ ユニバーシティ, リミテッド 核酸の送達のためのリポソーム製剤

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Caracciolo G. et al.,Surface adsorption of protein corona controls the cell internalization mechanism of DC-Chol-DOPE/DNA lipoplexes in serum,Biochim Biophys Acta,2010年,1798(3):536-43,<doi: 10.1016/j.bbamem.2009.11.007>
Grabbe S. et al.,Translating nanoparticulate-personalized cancer vaccines into clinical applications: case study with RNA-lipoplexes for the treatment of melanoma,Nanomedicine,2016年,11(20):2723-2734,<doi: 10.2217/nnm-2016-0275>
Sayour E.J. et al.,Cancer Vaccine Immunotherapy with RNA-Loaded Liposomes,Int J Mol Sci.,2018年09月23日,19(10):2890,<doi: 10.3390/ijms19102890>

Also Published As

Publication number Publication date
US20220287969A1 (en) 2022-09-15
EP3999034A4 (en) 2023-08-23
EP3999034A1 (en) 2022-05-25
JP2025138644A (ja) 2025-09-25
BR112022000925A2 (pt) 2022-05-17
WO2021016106A8 (en) 2022-02-10
WO2021016106A1 (en) 2021-01-28
AU2026205097A1 (en) 2026-07-16
KR20220035434A (ko) 2022-03-22
AU2020316335A1 (en) 2022-02-17
JP2022541586A (ja) 2022-09-26
AU2020316335B2 (en) 2026-04-02
CA3144388A1 (en) 2021-01-28

Similar Documents

Publication Publication Date Title
JP2025138644A (ja) 多層rnaナノ粒子
JP6363179B2 (ja) Rnaによるシェルを含む粒子
JP2023520506A (ja) Sars-cov-2に対する多層rnaナノ粒子ワクチン
US12514930B2 (en) Methods of sensitizing tumors to treatment with immune checkpoint inhibitors
AU2019265707B2 (en) Magnetic liposomes and related treatment and imaging methods
US20230096704A1 (en) Rna-loaded nanoparticles and use thereof for the treatment of cancer
US20230346700A1 (en) Multilamellar RNA Nanoparticles and Methods of Sensitizing Tumors to Treatment with Immune Checkpoint Inhibitors
CA3166934A1 (en) Rna-loaded nanoparticles and use thereof for the treatment of cancer
US20240238418A1 (en) Car t cell therapy method
US20250231177A1 (en) Method of characterizing tumors
WO2025207807A1 (en) Ctc rna-loaded nanoparticles and use thereof for the treatment of cancer
Liu Nanoparticle Mediated Chemo-Immunotherapy for Triple Negative Breast Cancer
WO2025031498A1 (zh) Toll样受体激动剂及其应用
US20160304558A1 (en) Cationic lipid formulations for regressing established tumor

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20220310

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20220310

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230714

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240520

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240702

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241001

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250128

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250528

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20251028

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251120

R150 Certificate of patent or registration of utility model

Ref document number: 7783628

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150